CLIENT's technology will reduce post-operative transfusions and deep infections in open-heart and orthopaedic joint replacement surgeries by >90% thereby reducing complications, hundreds of millions in cost and save lives.
CLIENT's technology combines 3 technologies into 1 for the first time:
1. Cell-Salvage which captures lost blood and prepare red blood cells for re-transfusion to the patient during a procedure
2. Fibrin Sealant, made from patient's own blood, actively seals difficult to stop bleeding wound surfaces after the procedure
3. Platelet Leukocyte Rich Plasma (PLRP) also produced from the patient's own blood containing growth factors and white blood cells which actively fight infectious microbes, promote tissue regeneration and wound healing
CLIENT has already received a positive ISR report from EU patent office on its patent pending.
CLIENT has invested _1.2MM in R&D, IP, prototype, market development and extensive clinical validations.
CLIENT has entered into two co-development partnerships with industry-leading companies that will invest _740K towards development costs against limited manufacturing rights.
Approximately 40% of the global 5.4MM open-heart and orthopaedic joint replacement surgery patients require blood transfusions from a donor. These patients are 6x more likely to die, stay on average 3 days longer in hospital and combined account for almost 20% or 8mio of all used transfused donor blood units in EU/US annually. The total annual cost impact to healthcare systems of transfusion and infection-related complications is estimated to be over _10BN in these two procedure categories alone.
CLIENT expects to achieve sales exceeding _50MM with EBIT >30% by 2020 working with strategic commercial partners. CLIENT has ongoing revenues from its distribution activities, has been profitable for three years.
The CLIENT needs _4.1MM over 3 years.